BBR 3464 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot be Treated With Surgery

Status unconfirmed · Phase 2

Conditions studied: Pancreatic Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BBR 3464 in treating patients who have locally advanced or metastatic pancreatic cancer that cannot be treated with surgery.

Key facts

Study ID

NCT00024362

Run by

Theradex

Starts

2001-05-01

Last updated by the study team

2008-07-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Arizona Oncology Associates — Tucson, Arizona, United States
• Alta Bates Comprehensive Cancer Center — Berkeley, California, United States
• Robert H. Lurie Comprehensive Cancer Center, Northwestern University — Chicago, Illinois, United States
• Albert B. Chandler Medical Center, University of Kentucky — Lexington, Kentucky, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Oklahoma Oncology Inc. — Tulsa, Oklahoma, United States
• Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group — Memphis, Tennessee, United States
• Cancer Center at the University of Virginia — Charlottesville, Virginia, United States
• Massey Cancer Center — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.